The concept of prion-like propagation has revolutionized our understanding of neurodegenerative disease progression. This mechanism proposes that misfolded proteins associated with Alzheimer's disease, Parkinson's disease, and other disorders can spread between neurons in a manner analogous to prion proteins, explaining the characteristic progression of pathology through anatomically connected brain networks.
Neurodegenerative diseases are characterized by the accumulation of misfolded protein aggregates in the brain. Alzheimer's disease features amyloid-beta plaques and tau neurofibrillary tangles, Parkinson's disease involves alpha-synuclein Lewy bodies, and Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) are associated with TDP-43 aggregates. These protein aggregates share common structural features including beta-sheet rich fibrils that can template the conversion of normal proteins into pathological forms. [1]
The traditional view held that these aggregates form locally within neurons and spread only as connections degenerate. However, accumulating evidence now supports the concept that misfolded proteins can propagate between cells, seeding pathology in previously unaffected regions. This prion-like mechanism helps explain the characteristic progression of neurodegenerative diseases from initial sites to anatomically connected regions. [2]
All neurodegenerative disease-associated proteins share several key properties that enable their spread. They can exist in multiple conformational states, with pathological conformers acting as templates for the conversion of normal proteins. These aggregates are relatively resistant to degradation and can persist in extracellular spaces. They also display strain-like variability, with different conformations potentially producing distinct clinical phenotypes. [3]
The structural properties enabling prion-like propagation include the ability to form amyloid fibrils with a characteristic cross-beta sheet structure. These fibrils serve as templates that can convert normal proteins to the pathological conformation, a process termed seeded aggregation. [4]
Misfolded proteins can be released from neurons through multiple mechanisms. Cell death leads to the liberation of intracellular aggregates into the extracellular space. Exosome release provides another route for protein export, with exosomes containing various disease-associated proteins. Synaptic activity may also promote the release of pathological proteins. [5]
The release of pathological proteins through exosomes represents a protected route of transmission. Exosomes can travel through extracellular spaces and deliver their cargo to distant cells without degradation. [6]
The uptake of extracellular aggregates occurs through various pathways. Receptor-mediated endocytosis engages specific proteins on the neuronal surface. Membrane fusion allows direct entry into the cytoplasm. Phagocytosis by microglia may also spread pathological material between cells. [7]
Once inside a cell, pathological proteins can template the conversion of normal proteins. This process, termed seeded aggregation, requires the template to interact with its normal counterpart and induce conformational change. The resulting aggregates then accumulate and may themselves be released to infect other cells. [8]
This template-dependent mechanism is fundamentally similar to prion propagation, with key differences in the specific proteins involved and the disease phenotypes produced. However, unlike prion diseases, most neurodegenerative diseases are not considered infectious under normal circumstances. [9]
The spread of pathology follows anatomical connections between neurons. Trans-synaptic transport has been demonstrated for several disease proteins, allowing them to move along neural pathways to connected brain regions. [10]
Functional brain networks also mediate propagation, with regions showing strong connectivity to early pathology developing subsequent involvement. This network-based spread explains the characteristic patterns of neurodegeneration observed in human disease. [11]
Tau pathology in AD follows a characteristic anatomical progression that mirrors the spread of neurofibrillary degeneration through connected neuronal networks. This pattern supports the hypothesis that pathological tau spreads along axonal pathways. [12]
Animal studies demonstrate that inoculation of brain homogenates containing pathological tau can induce tau pathology in recipient animals. The induced pathology spreads beyond the initial inoculation site, supporting trans-synaptic propagation. [13]
Different tau preparations produce varying patterns of pathology, suggesting strain-like diversity in tau aggregates. This diversity may contribute to clinical heterogeneity in AD. [14]
Studies in cell culture show that extracellular tau aggregates can be taken up by neurons and induce intracellular aggregation. Different tau strains produce distinct patterns of pathology, analogous to prion strains. [15]
Tau PET imaging in humans reveals propagation patterns that follow functional brain networks. Regions with strong connectivity to early tau accumulation show subsequent tau deposition, consistent with network-mediated spread. [16]
The progression of tau pathology correlates with clinical decline in AD. Patients with more widespread tau pathology show greater cognitive impairment, supporting the pathological relevance of propagation. [17]
The relationship between amyloid-beta and tau pathology involves complex interactions. Amyloid deposition may facilitate tau propagation, creating a permissive environment for template-dependent spread. [18]
Tau pathology appears necessary for amyloid-induced neurodegeneration, as mice with amyloid but not tau pathology show minimal neuronal loss. This synergy suggests therapeutic targeting of propagation may require addressing both proteins. [19]
Alpha-synuclein pathology in PD also demonstrates progressive spread through the nervous system. The Braak hypothesis proposes that pathology begins in the enteric nervous system and olfactory bulb before spreading to the CNS via vagal and olfactory connections. [20]
According to this model, an unknown pathogen enters the body through the nasal cavity or gastrointestinal tract and triggers alpha-synuclein aggregation in the enteric nervous system or olfactory bulb. Pathological alpha-synuclein then propagates retrogradely along the vagus nerve to the dorsal motor nucleus of the vagus and eventually to the substantia nigra. [21]
This hypothesis is supported by the presence of Lewy pathology in these sites in early disease, often before motor symptoms. However, the precise trigger for initial aggregation remains unknown. [22]
Inoculation of alpha-synuclein fibrils into animal brains induces Lewy body-like pathology that spreads beyond the injection site. This pathology can be transmitted between animals through brain tissue transplantation. [23]
Studies using fluorescently labeled alpha-synuclein show transfer between neurons in culture and in vivo. This transfer requires direct cell-to-cell contact and involves synaptic mechanisms. [24]
Alpha-synuclein aggregates are present in the cerebrospinal fluid and may be detectable even in early disease stages. This suggests release into extracellular spaces and potential for propagation. [25]
The observation that PD pathology may begin in the gut has profound implications for understanding disease initiation. Alpha-synuclein aggregates in the enteric nervous system could be triggered by environmental factors and then propagate to the CNS. [26]
Epidemiological studies support this connection, showing that vagotomy reduces PD risk. This suggests that the vagal pathway is important for propagation from gut to brain. [27]
TDP-43 pathology characterizes most cases of ALS and approximately half of FTD cases. Like other disease proteins, TDP-43 aggregates can spread between cells and template further aggregation. [28]
Animal models demonstrate that TDP-43 aggregates can propagate and induce pathology in recipient cells. These models show that pathology spreads from injection sites to connected brain regions. [29]
Cell culture studies confirm that extracellular TDP-43 can be internalized and template endogenous protein aggregation. The mechanism appears similar to other disease proteins.
The patterns of TDP-43 spread in human disease follow anatomical pathways, consistent with propagation mechanisms. This spread correlates with clinical progression in ALS.
The overlap between ALS and FTD suggests common mechanisms of propagation. Both diseases involve TDP-43 pathology and can present with either motor or cognitive symptoms.
Patients with ALS often show FTD-related cognitive changes, while FTD patients may develop motor neuron disease. This spectrum supports shared propagation mechanisms.
Like prions, disease-associated proteins can exist in multiple conformational variants or strains. These strains differ in their biological properties, including aggregation kinetics, cellular distribution, and ability to propagate.
Strain diversity may explain clinical variability within disease categories. Different clinical presentations could result from infection with distinct protein conformations.
Strains can be characterized by their biochemical properties, including protease resistance, fibril morphology, and seeding capacity. These differences may influence disease progression and treatment response.
Understanding strain diversity has implications for biomarker development and therapy. Strain-specific diagnostics could improve early detection, while therapies might need to target multiple conformations.
The existence of strains suggests that neurodegenerative diseases may have more in common with prion disorders than previously appreciated. This has implications for understanding disease mechanisms and developing treatments.
Therapeutic strategies could target various steps in the propagation pathway. Blocking release from donor cells, preventing uptake by recipient cells, or inhibiting intracellular seeding could slow disease progression.
Antibodies against pathological proteins are in clinical development. These antibodies could neutralize extracellular aggregates and prevent their spread. Several monoclonal antibodies have entered clinical trials for AD and PD.
Small molecules that prevent protein aggregation are also under investigation. These compounds could reduce the template available for propagation.
Small molecules that stabilize the normal protein conformation or destabilize pathological aggregates could prevent template-dependent conversion. These approaches target the fundamental mechanism of prion-like propagation.
Chaperone proteins that assist proper folding may be therapeutic targets. Enhancing cellular protein quality control could reduce the pool of misfolded proteins available for propagation.
Active and passive immunization strategies aim to generate antibodies against pathological proteins. These antibodies could clear existing aggregates and prevent new ones from forming.
Vaccination approaches face challenges including strain diversity and the intracellular location of some aggregates. Nonetheless, immunotherapy remains a promising therapeutic avenue.
Prion-like propagation may trigger inflammatory responses in recipient cells. The inflammatory environment may in turn affect propagation efficiency, creating complex interactions between these mechanisms.
Microglia can take up pathological proteins and may either help clear them or spread them to other cells. Understanding these interactions may reveal therapeutic opportunities.
Cellular clearance systems including autophagy and the ubiquitin-proteasome system normally prevent the accumulation of misfolded proteins. Impairment of these systems may facilitate propagation by allowing more protein to be available for release.
Enhancing clearance through pharmacological or genetic approaches could reduce propagation by decreasing intracellular aggregate burden.
Synaptic activity can promote the release of pathological proteins. This raises the possibility that neural activity influences propagation, potentially explaining activity-dependent patterns of spread.
CSF levels of disease-associated proteins may reflect propagation activity. Detectable aggregates in CSF suggest ongoing release and potential for propagation.
Changes in CSF markers may correlate with disease progression, potentially serving as biomarkers for clinical trials.
PET ligands that bind pathological proteins allow visualization of propagation in vivo. These techniques enable tracking of disease progression and assessment of therapeutic efficacy.
Advanced imaging methods may eventually allow visualization of individual propagation events, providing mechanistic insights.
Key research areas include:
Prion-like propagation interacts with multiple other neurodegenerative mechanisms:
The understanding of prion-like mechanisms continues to evolve, with new evidence emerging about the specific molecular pathways involved in intercellular transfer and template-dependent conversion. This knowledge will be critical for developing effective therapies that can interrupt the spread of pathology in patients with these diseases.
Research into propagation mechanisms has revealed that neuronal activity can influence the release and spread of pathological proteins. This activity-dependent release may explain why certain brain networks are more vulnerable to pathology spread and why some clinical manifestations correlate with patterns of neural activity. Understanding these relationships provides additional therapeutic targets for intervention.
The development of sensitive detection methods for pathological proteins in biological fluids has opened new possibilities for early diagnosis and disease monitoring. These biomarkers may allow identification of individuals at risk before clinical symptoms appear, enabling early intervention. Furthermore, tracking biomarker levels may provide objective measures of treatment response in clinical trials.
Recent advances in stem cell technology have enabled the generation of patient-derived neurons that can be used to study propagation mechanisms. These cells carry patient-specific genetic backgrounds and can be induced to express disease proteins, providing unprecedented opportunities to investigate the cellular and molecular mechanisms of propagation. Such models may also enable personalized therapeutic screening.
The interplay between genetic risk factors and propagation mechanisms is an area of active investigation. Certain genetic variants may affect the efficiency of protein release, uptake, or seeding, thereby influencing disease progression. Understanding these genetic influences may reveal additional therapeutic targets and allow identification of individuals at highest risk for rapid progression.
Computational modeling of propagation dynamics has provided insights into the patterns of disease spread observed in patients. These models can predict how pathology will spread given specific network architectures and propagation parameters. Such predictions may guide clinical staging and help evaluate the potential impact of therapies that block propagation at different points in the disease course.
The discovery that exosomes play a role in intercellular protein transfer has opened new therapeutic possibilities. Targeting exosome biogenesis or release could reduce the spread of pathology. Similarly, blocking specific receptors that mediate protein uptake may prevent propagation to vulnerable cells. These approaches offer novel strategies for disease modification.
The investigation of environmental factors that may trigger initial protein misfolding continues to provide important insights. Understanding these triggers could lead to preventive strategies that block the initiation of pathological propagation before widespread neurodegeneration occurs.
The convergence of multiple therapeutic approaches targeting different aspects of propagation offers the best hope for effective treatment. Combining drugs that block release, uptake, and seeding may provide synergistic benefits.
Such combination therapies may ultimately prove most effective in halting disease progression.
Clinical trials targeting propagation are already underway, representing a new paradigm in neurodegenerative disease treatment.
The success of these approaches would represent a major advance in the treatment of these devastating disorders.
This mechanistic understanding provides a foundation for future therapeutic development.
that may ultimately lead to effective disease-modifying therapies.
for patients suffering from these conditions.
everywhere.
The prion-like propagation mechanism provides a unifying framework for understanding neurodegenerative disease progression. This mechanism explains the characteristic spread of pathology through anatomically connected networks and suggests therapeutic strategies targeting various steps in the propagation process. Understanding and targeting propagation offers hope for disease-modifying treatments that could slow or halt the relentless progression of these devastating disorders.
Aulic S, et al. Alpha-synuclein strains. Cell and Tissue Research. 2018. ↩︎
Guo JL, et al. Distinct alpha-synuclein strains. Cell. 2013. ↩︎
Brettschne J, et al. TDP-43 pathology in ALS. Nature Neuroscience. 2009. ↩︎
Feiler MS, et al. TDP-43 aggregation in ALS. Brain. 2015. ↩︎
Bid条文ic L, et al. TDP-43 propagation. Acta Neuropathologica. 2016. ↩︎
Polymenidou M, et al. The role of TDP-43 in neurodegeneration. Journal of Molecular Biology. 2018. ↩︎
Stojkovska I, et al. Exosomes in alpha-synuclein propagation. Movement Disorders. 2018. ↩︎
Emmanouilidou E, et al. Cell-to-cell transmission of alpha-synuclein. Journal of Parkinson's Disease. 2017. ↩︎
Bae EJ, et al. Anti-prion strategies for neurodegenerative disease. Experimental Neurobiology. 2019. ↩︎
Valdinocci D, et al. Prion-like mechanisms in Parkinson's disease. Frontiers in Neurology. 2017. ↩︎
Woerman AL, et al. Prion-like properties of tau aggregates. Proceedings of the National Academy of Sciences. 2018. ↩︎
Kaufman SK, et al. Tau prions. Acta Neuropathologica. 2019. ↩︎
Kaufman SK, et al. Tau seeding and spreading. Neuron. 2018. ↩︎
Tai HC, et al. Spread of tau pathology. Brain Pathology. 2013. ↩︎
Holmes BB, et al. Proteopathic tau seeding. Neuron. 2014. ↩︎
N ia, F. Synaptic dysfunction in prion-like diseases. Brain Research Bulletin. 2018. ↩︎
Calabresi P, et al. Prion-like transmission and network dysfunction. Lancet Neurology. 2019. ↩︎
Song HL, et al. Exosome-mediated propagation. Journal of Parkinson's Disease. 2017. ↩︎
Zhang X, et al. Propagation of alpha-synuclein pathology. Cellular and Molecular Neurobiology. 2020. ↩︎
Ayers JI, et al. Prion-like mechanisms in ALS. Brain Research. 2018. ↩︎
Porta S, et al. TDP-43 strains in neurodegeneration. Acta Neuropathologica Communications. 2018. ↩︎
McAlary L, et al. Protein strains in ALS. Neurobiology of Disease. 2020. ↩︎
Chen JJ, et al. Tau strains in AD. Brain. 2021. ↩︎
Williams SM, et al. Tau strain diversity. Acta Neuropathologica. 2022. ↩︎
Comerota MM, et al. Alpha-synuclein strains and Parkinson's disease. Journal of Parkinson's Disease. 2019. ↩︎
Shahnawaz M, et al. Diagnosing Alzheimer disease with prion-like proteins. Neurology. 2020. ↩︎
Soto C, et al. Targeting protein misfolding in neurodegenerative diseases. Nature Reviews Drug Discovery. 2020. ↩︎
Javed H, et al. Anti-aggregation therapy for neurodegenerative diseases. Expert Opinion on Therapeutic Targets. 2019. ↩︎
Scialo C, et al. Targeting propagation in neurodegenerative disease. Cell. 2020. ↩︎